Summit Therapeutics Inc. (SMMT) Balance Sheet

The balance sheet has strengthened dramatically, but this is largely due to the $500M upfront payment to Akeso, which boosted cash and equity. However, the company remains pre-revenue, and the escalating R&D burn (from $24.5M to $157.7M quarterly) suggests this capital will be consumed rapidly. The trajectory indicates a deliberate shift to a high-risk, high-reward oncology strategy, with the balance sheet now reflecting the financial commitment to ivonescimab.

The dramatic deleveraging from 2024Q1 (D/E of 2.48) to 2026Q2 (0.03) reflects the conversion of debt into equity, likely through the Akeso deal and equity raises. However, the low leverage is misleading because the company's operating losses are accelerating, and the $419.4M cash balance may only cover about two quarters of current burn. Investors should monitor whether future financing will be dilutive or add debt, as the current balance sheet does not reflect the massive capital required for Phase III trials and potential commercialization.

The asset base is overwhelmingly cash, with negligible PPE and goodwill, reflecting a company that outsources manufacturing and focuses on R&D. This asset-light structure is typical for biotechs but means the balance sheet provides little collateral for debt. The $2.0M goodwill is immaterial, and the lack of significant intangibles suggests the company's value lies in its licensed asset, which is not on the balance sheet. This underscores the binary risk: if ivonescimab fails, the asset base would be largely cash, but that cash would be depleted by ongoing burn.

The equity base has grown from $35.2M to $630.0M, but this is primarily due to equity raises and the Akeso deal, not organic earnings. The accumulated deficit has expanded by $1.9B, reflecting heavy losses, and SBC has been a major non-cash expense, diluting existing shareholders. The quality of equity is low because it is built on future promises rather than retained earnings. Investors should monitor the pace of dilution, as continued SBC and future equity raises could further erode per-share value even if clinical trials succeed.

The current ratio of 6.96 appears strong, but it is inflated by the large cash balance relative to minimal current liabilities. The real liquidity concern is the cash runway: with quarterly operating losses of ~$220M, the $419.4M cash provides less than two quarters of runway. This suggests the company will need to raise capital imminently, likely through equity issuance, which could be dilutive. The balance sheet's liquidity is adequate for now but is rapidly deteriorating as clinical costs escalate.